Pediatric Blood and Cancer: Risk factors and surveillance for reduced bone mineral density in pediatric cancer survivors. Between 2003 and 2010, 475 survivors of childhood leukemia and solid tumors (excluding central nervous system tumors) were screened for decreased bone mineral density (BMD) using dual-energy X-ray absorptiometry (DXA). These screenings were conducted according to the consensus-based Children’s Oncology Group Long-Term Follow-Up (COG-LTFU) Guidelines. Current guidelines recommend DXA testing in survivors who have received treatment with steroids, methotrexate, or hematopoietic stem cell transplant (HSCT). The primary goal of the study was to assess the yield of detecting decreased BMD in a contemporary cohort of childhood cancer survivors.
